# Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)

> **NCT02991495** · PHASE4 · COMPLETED · sponsor: **Epicentre** · enrollment: 1630 (actual)

## Conditions studied

- Yellow Fever

## Interventions

- **BIOLOGICAL:** Stamaril, Sanofi Pasteur
- **BIOLOGICAL:** Yellow fever vaccine, Bio-Manguinhos
- **BIOLOGICAL:** Yellow fever vaccine, Institut Pasteur
- **BIOLOGICAL:** Yellow fever vaccine, Chumakov Institute
- **BIOLOGICAL:** Yellow fever vaccine, Chumakov Institute
- **BIOLOGICAL:** Yellow fever vaccine, Chumakov Institute

## Key facts

- **NCT ID:** NCT02991495
- **Lead sponsor:** Epicentre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-06
- **Primary completion:** 2018-02-21
- **Final completion:** 2021-12-31
- **Target enrollment:** 1630 (ACTUAL)
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991495, "Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02991495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*